Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.36 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.32 |
| ▸ | GABRE | P78334 | 1/20 | 0.32 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.32 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.32 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9768106 | 0.81 | — | — | |
| SCHEMBL471793 | 0.70 | — | — | |
| SCHEMBL8993949 | 0.68 | — | — | |
| SCHEMBL2460286 | 0.67 | TSHR (0.38) | TSHRSLC6A1SLC6A13BLMGABRP | |
| SCHEMBL6752598 | 0.65 | — | — | |
| SCHEMBL377963 | 0.65 | — | — | |
| SCHEMBL11498473 | 0.65 | TSHR (0.45) | TSHRSLC6A1SLC6A13BLMGABRP | |
| SCHEMBL13178314 | 0.62 | — | — | |
| SCHEMBL5912729 | 0.62 | — | — | |
| SCHEMBL27190625 | 0.62 | TSHR (0.38) | TSHRSLC6A1SLC6A13BLMGABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025215108-A1 | DUAL G9A/GSK-3ß INHIBITORS | UNIVERSITAT DE BARCELONA (ES) | 2025-10-16 | — | — | WO | disclosed |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2023-07-20 | — | — | US | disclosed |
| CN-107250110-A | The noval chemical compound of (RET) inhibitor is reset as transfection | 葛兰素史克知识产权发展有限公司 | 2017-10-13 | — | — | CN | disclosed |
| CN-106983751-A | Two ring substituted uracils and application thereof | 拜耳医药股份有限公司 | 2017-07-28 | — | — | CN | disclosed |
| CN-104395310-B | Bicyclic substituted uracils and their use | 拜耳药业股份公司 | 2017-05-03 | — | — | CN | disclosed |
| CN-105873919-A | Substituted uracils as chymase inhibitors | 拜耳医药股份有限公司 | 2016-08-17 | — | — | CN | disclosed |
| WO-2009114470-A2 | TETRAHYDROINDOLE AND TETRAHDYROINDAZOLE AS HSP90 INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | TSHR 2427/4885SLC6A1 4324/4885SLC6A13 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.